Some major progress in kidney cancer and head and neck cancer was announced at the ASCO meeting in Atlanta, and the Audio Journal of Oncology has all the details, plus expert comment from Dean Bajorin of Memorial Sloan Kettering Cancer Center in New York.

- Sunitinib is superior to interferon alpha as first line therapy in metastatic kidney cancer. Robert Motzer from the Memorial Sloan Kettering Cancer Center in New York told the ASCO conference about his team’s ground-breaking phase III trial with this drug
- In high risk advanced renal cell carcinoma, temsirolimus has proved more effective than interferon alpha – that’s according to a study presented by Gary Hudes, of the Fox Chase Cancer Center in Philadelphia
- A new three-drug “induction” chemotherapy regimen involving docetaxel has produced a significant benefit in advanced head and neck cancer. Marshall Posner of the Dana-Farber Cancer Institute had the data at the ASCO meeting